These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 325742)

  • 1. Immunologic reconstitution of patients with primary immunodeficiency diseases and cancer after treatment with thymosin.
    Goldstein AL; Thurman GB; Rossio JL; Costanzi JJ
    Transplant Proc; 1977 Mar; 9(1):1141-4. PubMed ID: 325742
    [No Abstract]   [Full Text] [Related]  

  • 2. Thymosin for immunodeficiency diseases and cancer.
    Goldstein AL; Rossio JL
    Compr Ther; 1978 Feb; 4(2):49-57. PubMed ID: 624213
    [No Abstract]   [Full Text] [Related]  

  • 3. Thymosin treatment of children with primary immunodeficiency disease.
    Wara DW; Ammann AJ
    Transplant Proc; 1978 Mar; 10(1):203-9. PubMed ID: 305674
    [No Abstract]   [Full Text] [Related]  

  • 4. [Regular trisomy 21 and combined immunodeficiency. Ineffectiveness of thymosin].
    Calvani M; Aiuti F; Felici N; D'Amelio R; Picchio E
    Minerva Pediatr; 1979 Dec; 31(23):1691-7. PubMed ID: 162325
    [No Abstract]   [Full Text] [Related]  

  • 5. Thymosin: basic properties and clinical application in the treatment of immunodeficiency diseases and cancer.
    Marshall GD; Thurman GB; Low TL; Goldstein AL
    Recent Results Cancer Res; 1980; 75():100-5. PubMed ID: 6262885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thymosin: basic properties and clinical potential in the treatment of patients with immunodeficiency diseases and cancer.
    Goldstein AL
    Antibiot Chemother (1971); 1978; 24():47-59. PubMed ID: 350140
    [No Abstract]   [Full Text] [Related]  

  • 7. Thymosin and the endocrine thymus.
    Schulof RS; Goldstein AL
    Adv Intern Med; 1977; 22():121-43. PubMed ID: 320839
    [No Abstract]   [Full Text] [Related]  

  • 8. In vitro and in vivo enhancement of mixed lymphocyte culture reactivity by thymosin in patients with primary immunodeficiency disease.
    Wara DW; Barrett DJ; Ammann AJ; Cowan MJ
    Ann N Y Acad Sci; 1979; 332():128-34. PubMed ID: 161150
    [No Abstract]   [Full Text] [Related]  

  • 9. Research with immunoactive agents.
    Gunby P
    JAMA; 1981 Jul; 246(3):205. PubMed ID: 7017181
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of thymosin in the treatment of primary immunodeficiency diseases and cancer.
    Goldstein AL; Cohen GH; Rossio JL; Thurman GB; Brown CN; Ulrich JT
    Med Clin North Am; 1976 May; 60(3):591-606. PubMed ID: 131889
    [No Abstract]   [Full Text] [Related]  

  • 11. T-cell stimulator undergoes diverse testing.
    Gunby P
    JAMA; 1982 Aug; 248(7):807. PubMed ID: 7047781
    [No Abstract]   [Full Text] [Related]  

  • 12. Overview of thymosin activity.
    Marshall GD; Low TL; Thurman GB; Hu SK; Rossio JL; Trivers G; Goldstein AL
    Cancer Treat Rep; 1978 Nov; 62(11):1731-7. PubMed ID: 215305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Gordon Wilson lecture. The history of the development of thymosin: chemistry, biology and clinical applications.
    Goldstein AL
    Trans Am Clin Climatol Assoc; 1977; 88():79-94. PubMed ID: 331647
    [No Abstract]   [Full Text] [Related]  

  • 14. Thymosin therapy in the DiGeorge syndrome.
    Barrett DJ; Wara DW; Ammann AJ; Cowan MJ
    J Pediatr; 1980 Jul; 97(1):66-71. PubMed ID: 7381650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experiences with thymosin in primary immunodeficiency disease.
    Astaldi A; Astaldi GC; Wijermans P; Dagna-Bricarelli F; Kater L; Stoop JW; Vossen JM
    Cancer Treat Rep; 1978 Nov; 62(11):1779-85. PubMed ID: 215306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Results and prospects of using thymosin for the purpose of regulating the immune system in different pathological processes and states].
    Grinevich IuA; Kamenets LIa
    Zh Mikrobiol Epidemiol Immunobiol; 1979 Dec; (12):9-15. PubMed ID: 390944
    [No Abstract]   [Full Text] [Related]  

  • 17. Biological response modifiers and their promise in clinical medicine.
    Attallah AM; Yeatman TJ; Johnson RP; Petricciani JC
    Pharmacol Ther; 1982; 19(3):435-54. PubMed ID: 6201933
    [No Abstract]   [Full Text] [Related]  

  • 18. Severe combined immunodeficiency with cartilage-hair hypoplasa: in vitro response to thymosin and attempted reconstitution.
    Steele RW; Britton HA; Anderson CT; Kniker WT
    Pediatr Res; 1976 Dec; 10(12):1003-5. PubMed ID: 995498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo responses to thymosin in severe combined immunodeficiency.
    Mawhinney H; Gleadhill VF; McCrea S
    Clin Immunol Immunopathol; 1979 Oct; 14(2):196-203. PubMed ID: 314879
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunotherapy of cancer with thymosin.
    Rossio JL; Goldstein AL
    World J Surg; 1977 Sep; 1(5):605-16. PubMed ID: 602234
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.